Search Videos and More

Showing 1 - 12 of 45 results

Previous| 1 | 2 | 3 ...4 |Next


Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain News

Researchers Uncover Key Actor in Spread of Breast Cancer to the Brain

When breast cancer metastasizes, it often heads for the brain, where it can be exceptionally difficult to root out. The key to preventing the spread of the cancer, or thwarting it if it does reach the brain, is to understand the mechanism that turns stationary tumor cells into nomadic intruders. 
Breast Cancer Research: New Studies Show How Post-Treatment Lifestyle Choices Shape Long-Term Outcomes After Diagnosis News

Breast Cancer Research: New Studies Show How Post-Treatment Lifestyle Choices Shape Long-Term Outcomes After Diagnosis

Three studies led by Dana-Farber Cancer Institute researchers have encouraging implications for patients with breast cancer.
Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer News

Antibody-Drug Conjugate Found Effective Against Brain Metastases in Patients with HER2-Positive Breast Cancer

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2-positive breast cancer.
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024 News

Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024

Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention News

Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention

Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds News

Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds

A year of treatment with a medicine made of an antibody and chemotherapy drug has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients, a team led by Dana-Farber Cancer Institute researchers has found.
Patients With a History of Breast Cancer who Desire Pregnancy Document

Patients With a History of Breast Cancer who Desire Pregnancy

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.
Most Young Women Treated For Breast Cancer Can Have Children, Study Shows News

Most Young Women Treated For Breast Cancer Can Have Children, Study Shows

In a study of nearly 200 young women who have survived breast cancer, most of those who tried to conceive were able to become pregnant and give birth.
Breast Cancer Trial Aims to Improve Treatment for Men News

Breast Cancer Trial Aims to Improve Treatment for Men

Over the past 30 years, outcomes have improved dramatically for women with breast cancer. There are many new treatments, including hormone therapies and CDK4/6 inhibitors. In contrast, there has been no improvement in the outcomes for men with breast cancer. And current guidelines don’t support the use of newer therapies in men. Male breast cancer accounts for just 1% of all cases of breast cancer. Advancing care for a rare group requires a focused effort, so Jose Pablo Leone, MD, has invested energy into designing and leading a clinical trial for men with breast cancer.
Antibody-Drug Conjugates: A Cancer Therapy Revolution News

Antibody-Drug Conjugates: A Cancer Therapy Revolution

Dana-Farber researchers explore how a novel therapy may benefit patients
Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer Document

Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction News

Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction

Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.

Showing 1 - 12 of 45 results

Previous| 1 | 2 | 3 ...4 |Next